Growth Metrics

Armata Pharmaceuticals, Inc. (ARMP) EBIT Margin (2016 - 2018)

Armata Pharmaceuticals' EBIT Margin history spans 6 years, with the latest figure at 829.08% for Q4 2018.

  • For Q4 2018, EBIT Margin rose 1265408.0% year-over-year to 829.08%; the TTM value through Dec 2018 reached 2709.47%, up 1675817.0%, while the annual FY2024 figure was 762.14%, 291085.0% up from the prior year.
  • EBIT Margin for Q4 2018 was 829.08% at Armata Pharmaceuticals, down from 2852.44% in the prior quarter.
  • Across five years, EBIT Margin topped out at 2852.44% in Q3 2018 and bottomed at 73140.91% in Q4 2016.
  • The 5-year median for EBIT Margin is 3141.09% (2014), against an average of 10355.79%.
  • The largest annual shift saw EBIT Margin tumbled -8311197bps in 2014 before it skyrocketed 6131591bps in 2017.
  • A 5-year view of EBIT Margin shows it stood at 2571.29% in 2014, then skyrocketed by 34bps to 1697.9% in 2015, then plummeted by -4208bps to 73140.91% in 2016, then surged by 84bps to 11825.0% in 2017, then surged by 107bps to 829.08% in 2018.
  • Per Business Quant, the three most recent readings for ARMP's EBIT Margin are 829.08% (Q4 2018), 2852.44% (Q3 2018), and 11825.0% (Q4 2017).